Impact on the optimization of treatment and the clinic of inflammatory bowel disease through pharmaceutical monitoring
- At: Seville (Spain) (2022)
- Type: Poster
- Poster code: HPS-089
- By: LUNA REINA, ROSA MARIA ()
- Co-author(s): Dra. ZENAIDA MARTINEZ-ECHEVARRIA GIL-DELGADO, PHARMACY (HOSPITAL PUNTA DE EUROPA (ALGECIRAS), ALGECIRAS, Spain)
SRA ROSA MARIA LUNA REINA, FARMACIA HOSPITALARIA (HOSPITAL PUNTA DE EUROPA (ALGECIRAS), ALGECIRAS, Spain)
Sr JAVIER ROMERO PUERTO, FARMACIA HOSPITALARIA (HOSPITAL PUNTA DE EUROPA (ALGECIRAS), ALGECIRAS, Spain)
Optimization of infliximab treatment in inflammatory bowel disease (IBD) through pharmacokinetics.
To assess the impact of monitoring infliximab plasma levels in patients with IBD.
Retrospective descriptive research, which included patients with IBD who were asked for infliximab plasma levels between.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019